Rxight genetic testing panel can help ADHD patients assess prescription drugs

In 2006, the FDA warned that ADHD medicines could lead to psychotic events.
In 2006, the FDA warned that ADHD medicines could lead to psychotic events. | File image
MD Labs, the makers of the Rxight genetic testing panel, recently announced that the U.S. Food and Drug Administration warns that ADHD medications can cause adverse psychiatric effects and that the Rxight genetic testing can help patients better assess prescription drugs.
It its 2006 briefing “Adverse Events Associated with Drug Treatment of ADHD: Review of Post marketing Safety Data,” the FDA warned that ADHD medicines could lead to psychotic events. The FDA presented its findings to the Pediatric Advisory Committee.
“The most important finding of this review is that signs and symptoms of psychosis or mania, particularly hallucinations, can occur in some patients with no identifiable risk factors, at usual doses of any of the drugs currently used to treat ADHD,” the FDA noted its review.
MD Labs noted that stimulant medications prescribed for ADHD include Focalin (dexmethylphenidate hydrochloride), Adderall (amphetamine), Dexedrine (dextroamphetamine), Vyvanse (lisdexamfetamine) and Ritalin (methylphenidate hydrochloride).
According to MD Labs, all of these products are tested under the Rxight genetics testing panel, which looks to see whether a patient’s body can candle the medications.
Want to get notified whenever we write about MD Labs/Rxight ?
Next time we write about MD Labs/Rxight, we'll email you a link to the story. You may edit your settings or unsubscribe at any time.
Organizations in this story

MD Labs/Rxight 10715 Double R Blvd Reno, NV 89521